|Poll|August 29, 2022

POLL: Which September FDA Approval Are You Looking Forward To?

Click here to answer this week's poll.

Which September FDA Approval Are You Looking Forward To?

Revance's daxibotulinumtoxinA for glabbelar lines; PDUFA September 8, 2022
Bristol Myers Squibb's deucravacitinib for psoriasis; PDUFA September 10, 2022
Sanofi/Regneron's dupilumab for prurigo nodularis; PDUFA September 30, 2022

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME